QUATRX ANNOUNCES THE APPOINTMENT OF JEFFERY BRINZA AS GENERAL COUNSEL

[Released July 18, 2005]

ANN ARBOR, MI—QuatRx Pharmaceuticals Company today announced the appointment of Jeffery M. Brinza to the position of general counsel. In this role Mr. Brinza will be responsible for overseeing the company's legal matters related to intellectual property, corporate partnerships and licensing opportunities, clinical trials, financing and other areas.

"Jeff brings a wealth of legal skill and experience that will be important assets as QuatRx prepares for many upcoming milestones in research, product development and corporate partnering opportunities," said Robert Zerbe, chief executive officer of QuatRx.

Mr. Brinza most recently served as a partner at Brinza & Associates, providing legal representation for various pharmaceutical, life science and technology companies, including Abbott Laboratories. He also served as vice president and assistant general counsel at Warner-Lambert Company where he was responsible for overseeing all commercial legal aspects of the Parke-Davis Pharmaceutical Research and Development Division headquartered in Ann Arbor. He has negotiated research, development and commercialization transactions with numerous biotechnology and pharmaceutical companies worldwide.

"Many factors, including the recent merger with Hormos Medical and the continuing progress in product development, make this an especially exciting time at QuatRx, and I am very pleased to be joining a strong and experienced management team to help the company continue to build momentum in the years ahead," said Mr. Brinza.

About QuatRx

QuatRx Pharmaceuticals Company, a biopharmaceutical company, focuses on research and development of therapeutic compounds primarily for the treatment of major endocrine, metabolic and cardiovascular diseases, especially dyslipidemia and endocrine diseases of aging. QuatRx has its headquarters in Ann Arbor, Michigan, with a significant presence in Europe through Hormos Medical Corp. (a wholly-owned subsidiary of QuatRx Pharmaceuticals Company), located in Turku, Finland. QuatRx's robust pipeline includes four compounds in clinical development. The research activities of the company are based on its expertise in tissue-specific steroid hormone effects at the molecular and cellular level. With significant financial backing from top-tier venture capital firms and strong development capabilities, QuatRx continues to advance and expand its portfolio of development-stage compounds.

Back to News Home